Industry and academic scientists are working together to figure out when and how best to use phenotypic screening in drug discovery.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Perfused Three-dimensional Organotypic Culture of Human Cancer Cells for Therapeutic Evaluation
Scientific Reports Open Access 25 August 2017
-
Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening
Nature Communications Open Access 17 July 2017
-
Predicting the Reliability of Drug-target Interaction Predictions with Maximum Coverage of Target Space
Scientific Reports Open Access 19 June 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Mullard, A. The phenotypic screening pendulum swings. Nat Rev Drug Discov 14, 807–809 (2015). https://doi.org/10.1038/nrd4783
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4783
This article is cited by
-
Principle and design of pseudo-natural products
Nature Chemistry (2020)
-
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Nature Reviews Drug Discovery (2017)
-
Predicting the Reliability of Drug-target Interaction Predictions with Maximum Coverage of Target Space
Scientific Reports (2017)
-
Perfused Three-dimensional Organotypic Culture of Human Cancer Cells for Therapeutic Evaluation
Scientific Reports (2017)
-
Prioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening
Nature Communications (2017)